LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Polysome Screen Identifies Cancer Related MicroRNAs

By LabMedica International staff writers
Posted on 04 Sep 2018
Image: A micrograph of a pleural fluid cytopathology specimen showing mesothelioma (Photo courtesy of Wikimedia Commons).
Image: A micrograph of a pleural fluid cytopathology specimen showing mesothelioma (Photo courtesy of Wikimedia Commons).
An international research team has developed a polysome-based method for detecting microRNAs (miRNAs) that act to promote or sustain growth of malignant mesothelioma and other types of cancer.

MicroRNAs are short RNA molecules about 22 nucleotides in length. Essentially, miRNAs specifically target certain messenger RNAs (mRNAs) to prevent them from coding for a specific protein. The expression of miRNAs in cancer has been widely studied and has allowed this activity to be classified as oncomir (also oncomiR) or oncosuppressor.

The dysregulation of oncomirs has been associated with specific cancer forming events such as malignant transformation and metastasis. Some oncomir genes are oncogenes, in that overexpression of the gene leads to cancerous growth. Other oncomir genes are tumor suppressors in a normal cell, so that under expression of the gene leads to cancerous growth.

In order to identify biologically active oncomirs, investigators at the National Institute of Molecular Genetics (Milan, Italy) and their collaborators in Italy and the United States developed a screen for miRNAs acting on the polysomes of malignant mesothelioma (MPM) cells. A polysome (or polyribosome) is a complex comprising an mRNA molecule and two or more ribosomes that act to translate mRNA instructions into polypeptides.

They investigators reported in the August 2, 2018, online edition of the journal Cancer Research that only a small percentage of expressed miRNAs physically associated with polysomes. On polysomes, they identified miRNAs already characterized in MPM, as well as novel ones like miR-24-3p, which acted as a pro-migratory miRNA in all cancer cells tested. They found that miR-24-3p positively regulated the activity of the enzyme Rho-GTP, a kinase involved in regulating the shape and movement of cells by acting on the cytoskeleton. In contrast, inhibition of miR-24-3p reduced growth in MPM cells.

Among the specific targets of miR-24-3p was cingulin, a tight junction protein that inhibited Rho-GTP activity. Overexpression of miR-24-3p was found to only partially inhibit cingulin mRNA but to completely eliminate cingulin protein, confirming its action via translational repression. This finding confirmed that miR-24-3p was an oncomir, and suggested that identification of polysome-associated miRNAs efficiently sorted out biologically active miRNAs from inactive ones.

“We have identified a novel approach for identifying relevant miRNA in cancer biology,” said senior author Dr. Stefano Biffo, professor of cell biology at the University of Milan (Italy) and group leader at the National Institute of Molecular Genetics. “By examining the polyribosomes where translation occurs, this "focused" search has allowed us to identify that miR-24-3p (a particular miRna) expression is relevant to cancer progression and metastasis.”

Related Links:
National Institute of Molecular Genetics
University of Milan

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Gold Member
Radial Immunodiffusion Assay
Radial Immunodifusion - C3 ID

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more